WO1997019932A1

WO1997019932A1 - 2-thioxo-imidazolidin-4-one derivatives and their use for increasing hdl cholesterol concentration

Info

Publication number: WO1997019932A1
Application number: PCT/US1996/019164
Authority: WO
Inventors: Hassan Mahmoud Elokdah; Sie-Yearl Chai; Theodore Sylvester Sulkowski; Donald Peter Strike
Original assignee: American Home Products Corporation
Priority date: 1995-11-28
Filing date: 1996-11-25
Publication date: 1997-06-05
Also published as: AU1127697A; CA2238762A1; JP2000501100A; EP0876355A1

Abstract

Compounds and a method for increasing the HDL cholesterol concentration in the blood of a mammal in need of increased HDL cholesterol blood concentration, which comprises administering to said mammal, orally or parenterally, a compound of formula (I) wherein R is alkyl; a substituted or unsubstituted aromatic N, O or S heterocycle; substituted or unsubstituted aryl, arylalkyl, benzhydryl or indanyl, in which the substituents are one to three members independently selected from the group consisting of alkyl, alkoxy, alkylthio, alkenyl, alkynyl, halo, perfluoroalkyl, perfluoroalkoxy or hydroxy; and R1 is aryl, alkyl, alkenyl, alkynyl or substituted aryl where the substituents are one to three members independently selected from the group consisting of alkyl, alkoxy, alkylthio, alkenyl, alkynyl, halo, perfluoroalkyl, perfluoroalkoxy or hydroxy.

Description

2-THI0X0-IMIDAZ0LIDIN-4-0NE DERIVATIVES AND THEIR USE FOR INCREASING HDL CHOLESTEROL CONCENTRATION .

The present invention relates to compounds for increasing HDL cholesterol concentration in the blood of a mammal, to their use in this method of treatment, to pharmaceutical compositions containing the compounds and to a process for preparation of the compounds.

Numerous studies have demonstrated that both the risk of coronary heart disease (CHD) in humans and the severity of experimental atherosclerosis in animals are inversely correlated with serum HDL cholesterol (HDL-C) concentrations (Russ et al, Am. J. Med., H (1951) 480-493; Gofman et al, Circulation. 34 (1966) 679-697; Miller and Miller, Lancet. 1 (1975) 16-19; Gordon et al, Circulation. 79_(1989) 8-15; Stampfer et al, N. Engl. J. Med.. 325 (1991 . 373-381; Badimon et al, Lab. Invest.. 6ϋ (1989) 455-461). Atherosclerosis is the process of accumulation of cholesterol within the arterial wall which results in the occlusion, or stenosis, of coronary and cerebral arterial vessels and subsequent myocardial infarction and stroke. Angiographical studies have shown that elevated levels of some HDL particles appears to be correlated with a decrease in the number of sites of stenosis in the coronary arteries of humans ( Miller et al. Br. Med. J .. 282 (1981 , 1741-1744).

There are several mechanisms by which HDL may protect against the progression of atherosclerosis. Studies in vitro have shown that HDL is capable of removing cholesterol from cells (Picardo et al, Arteriosclerosis. 6 (1986) 434-441). Data of this nature suggests that one antiatherogenic property of HDL may lie in its ability to deplete tissues of excess free cholesterol and eventually lead to the delivery of this cholesterol to the liver (Glomset. J. Lipid Res.. 9 (1968) 155-167). This has been supported by experiments showing efficient transfer of cholesterol from HDL to the liver (Glass et al, Circulation. 66 (Suppl. I) (1982) 102; MacKinnon et al, J. Biol. Chem.. 261 (1986) 2548-2552). In addition, HDL may serve as a reservoir in the circulation for apoproteins necessary for the rapid metabolism of triglyceride-rich lipoproteins (Grow and Fried, J. Biol. Chem.. 253 (1978) 1834-1841; Lagocki and Scanu, J. Biol. Chem.. 255 (1980) 3701-3706; Schaefer et al, J. Lipid Res.. 23 (1982) 1259-1273). Accordingly, agents which increase HDL cholesterol concentrations are useful as anti-atherosclerotic agents, particularly in the treatment of dyslipoproteinemias and coronary heart disease.

US 5,137,904 discloses a group of thiohydantoin derivatives of the formula

in which Z is alkyl, phenylalkyl, phenyl or substituted phenyl, where the substituent is a halogen, alkyl, alkoxy or halogenated alkyl group; X is phenyl, halophenyl, alkyl, alkenyl, or alkynyl; and Y is S or O. These compounds inhibit collagen-induced and ADP-induced platelet aggregation.

EP 0584694 andWO 93/18057 disclose a group of imidazolidin-3-yl benzoyl or alkanoyl amino acid derivatives as inhibitors of cell-cell adhesion for use in inhibition of thrombocyte aggregation, metastasis and osteoclast formation. Chronic administration for prevention of arteriosclerosis and thrombosis is disclosed.

in which Y = -(CH2)n-CO- or -Ph-CO- .

JP 04,297,461 discloses a group of 2-thiohydantoin compounds of the following formula, said to be useful as anti-bacterial, anti-viral, anti-inflammatory and anti-rheumatic agents:

where R* is lower alkyl, lower alkenyl, phenyl(lower)alkyl or substituted phenyl with 1-3 groups chosen from lower alkyl, lower alkoxy, halogen, lower alkoxycarbonyl or hydroxy;

R2 is either hydrogen or alkanoyl; and R3 is hydrogen, lower alkyl, phenyl, phenyl (lower) alkyl, or a lower alkylthio, lower alkyl group that can be substituted with one to three phenyl groups that have had a lower alkoxy group.

EP 0578516 discloses a group of 2-thiohydantoins, said to be useful anti- androgenic agents for treatment of various cancer, of the formula :

where X is oxygen or sulfur; Y is oxygen, sulfur or NH

Rl and R^ are cyano, nitro, halogen, trifluoromethyl, or a free or esterified carboxylic acid or salt;

R3 is hydrogen, alkyl, alkenyl, alkynyl, aryl or aryl-alkyl; R and R^ are hydrogen, optionally substituted alkyl, or cycloalkyl. US 5,411 ,981 discloses compounds closely related to EP 0578516, supra, where R^ and R^ are both methyl.

US 3,923,994 discloses a group of 3-aryl-2-thiohydantoin derivatives of the following formula, which have anti-arthritic activity:

where R^ and R^ are hydrogen, chloro, bromo, fluoro or alkyl of 1-2 carbon atoms.

JP 73 87,030 discloses a group of 3-phenyl-2-thiohydantoin derivatives useful as herbicides. US 4,473,393 discloses a group of pesticidal thiohydantoin compositions.

In accordance with this invention there is provided a compound of formula I:

I wherein

R is alkyl of 1 to 6 carbon atoms; a substituted or unsubstituted aromatic N, O or S heterocycle having 4 to 6 carbon and one hetero ring members; substituted or unsubstituted aryl of 6 to 10 carbon atoms, arylalkyi of 7 to 12 carbon atoms, benzhydryl or indanyl , in which the substituents are one to three members independendy selected from the group consisting of alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon ations, alkylthio of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, halo, perfluoroalkyl of 1 to 6 carbon atoms, perfluoroalkoxy of 1 to 6 carbon atoms or hydroxy; and

Rl is aryl of 6 to 10 carbon atoms, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms or substituted aryl of 6 to 10 carbon atoms where the substituents are one to three members independently selected from the group consisting of alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon ations, alkylthio of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, halo, perfluoroalkyl of 1 to 6 carbon atoms, perfluoroalkoxy of 1 to 6 carbon atoms or hydroxy, for use in the treatment of mammals.

A preferred embodiment of the invention provides a compound of formula I in which R is substituted phenyl where the substituents are two members of the group consisting of alkyl of 1 to 6 carbon atoms, perfluoroalkoxy of 1 to 6 carbon atoms, halo, or ortho substituted trimethylene or tetramethylene and R^ is alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms or alkynyl of 2 to 6 carbon atoms.

Another preferred embodiment of the invention provides a compound of formula I in which R is substituted phenyl where the substituents are a halo and an alkyl group of 1 to 3 carbon atoms or ortho substituted trimethylene and R^ is alkyl of 1 to 3 carbon atoms, alkenyl of 2 to 4 carbon atoms or alkynyl of 2 to 4 carbon atoms.

Another preferred embodiment of the invention provides a compound of formula I in which R is substituted phenyl where the substituents are chloro or fluoro in the 4- or 5- position and an alkyl group of 1 to 3 carbon atoms and R¹ is alkyl of 1 to 3 carbon atoms, alkenyl of 2 to 4 carbon atoms or alkynyl of 2 to 4 carbon atoms. Certain of the compounds of the present invention are novel and comprise a further aspect of the present invention. Thus, according to a further aspect of the present invention there is provided a compound of formula I as described above wherein Rl is alkyl of 1 to 6 carbon atoms and R is alkyl of 1 to 6 carbon atoms, naphthyl, benzhydryl, fluorophenylmethyl, phenethyl, l-(fluorophenyl)ethyl, 5-chloro- 2-methoxyphenyl, trifluoromethoxyphenyl, trifluoromethylphenyl, methy lsulfanyl- phenyl, pyridyl or the group of formula II

where R^, R^ and R^ together are 2-chloro, 4-fluoro, 2,4-chloro or 2,6- chloro, or

R2 is hydrogen, R^ is a halogen in 3-position and R^ is alkyl of 1 to 6 carbon atoms in

4-position, or R^ is alkyl of 1 to 6 carbon atoms and R^ and R^ are, independently, hydrogen or alkyl of 1 to 6 carbon atoms or R^ is a halogen and R^ is hydrogen; or

Rl is alkenyl of 2 to 6 carbon atoms, R is is the group of formula II where R^ is alkyl of 1 to 6 carbon atoms and R^ and R^ are, independendy, hydrogen or alkyl of 1 to 6 carbon atoms, or R^ is hydrogen and R^ and R^ taken together are ortho substituted trimethylene or tetramethylene, or R^ is alkyl of 1 to 6 carbon atoms,

R3 is halogen and R^ is hydrogen, or R^ is hydrogen, R^ is halogen in 3-position and

R is alkyl of 1 to 6 carbon atoms in 4-position; or when Rl is alkynyl of 2 to 6 carbon atoms, R is a group of formula II where any two of R^, R3 and R^ are, independently, alkyl of 1 to 6 carbon atoms, halo, perfluoralkyl of 1 to 6 carbon atoms, perfluoralkoxy of 1 to 6 carbon atoms, or, taken together, are ortho substituted trimethylene or tetramethylene; or when Rl is aryl of 6 to 10 carbon atoms or arylalkyi of 7 to 12 carbon atoms, R is the group of formula II where R² is alkyl of 1 to 6 carbon atoms, R³ is a halogen and R⁴ is hydrogen, or R² is hydrogen, R³ is a halogen in 3-position and R⁴ is alkyl of 1 to 6 carbon atoms in 4- position.

When any of R, R¹' R², R³ or R⁴ is alkyl it is preferably alkyl of 1 to 3 carbon atoms, especially methyl or ethyl, or any two of R², R3 and R⁴ when taken together are ortho substituted trimethylene or tetramethylene.

When Rl is alkenyl of 2 to 6 carbon atoms it is preferably allyl, When R² or R³ are halogen they are preferably independendy, chlorine or fluorine, especially in the 2-, 4-, and/or -6 positions. When R² or R³ are perfluoralkyl of 1 to 6 carbon atoms, perfluoralkoxy of 1 to 6 carbon atoms

When Rl is alkynyl of 2 to 6 carbon atoms it is preferably ethynyl, propargyl or butynyl, especially prop-2-ynl.

When R is aryl of 6 to 10 carbon atoms it is preferably, phenyl or naphthyl, the latter being preferably, 2-naphthyl. When R is aralkyl of 7 to 12 carbon atoms, it is preferably benzyl or phenethyl.

When R is fluorophenylmethyl, it is preferably 4-fluorophenylmethyl.

When R is l-(fluorophenyl)ethyl, it is preferably l-(4-fluorophenyl)ethyl. When R is trifluoromethoxyphenyl, it is preferably 4-trifluoro-methoxyphenyl. When R is methylsulfanylphenyl, it is preferably 2-methylsulfanylphenyl. When R is pyridyl, it is preferably 3-pyridyl.

The most preferred compounds of this invention based upon their potency and overall activity profile in the standard experimental test model are:

3-(5-Chloro-2-methylphenyl)- 1 -methyl-2-thioxo-imidazolidin-4-one 3-(3-Chloro-2-methylphenyl)- 1 -methyl-2-thioxo-imidazolidin-4-one

3-(4-Chloro-2-methylphenyl)-l-meuιyl-2-thioxo-imidazolidin-4-one 3-(Indan-5-yl)- 1 -methyl-2-thioxo-imidazolidin-4-one 3-(2,6-Diisopropylphenyl)- 1 -methyl-2-thioxo-imidazolidin-4-one 3-(2-Ethyl-6-isopropylphenyl)-l-methyl-2-thioxo-imidazolidin-4-one 3- (2-Ethyl-6-methylphenyl)- 1 -methyl-2-thioxo-imidazolidin-4-one

3-(5-Chloro-2-methylphenyl)-l-ethyl-2-thioxo-imidazolidin-4-one 3-(2,6-Dichlorophenyl)- 1 -ethyl-2-thioxo-imidazolidin-4-one l-Ethyl-3-(4-fluorophenyl)--2-thioxo-irnidazolidin-4-one l-Ethyl-2-Λioxo-3-(4-trifluoromethoxyphenyl)-imidazohdin-4-one 3-(2,6-Dimethylphenyl)-l-ethyl-2-thioxo-imidazolidin-4-one l-Ethyl-3-irøbutyl-2-tMoxo-imidazolidin-4-one 3-(2-Chlorophenyl)- 1 -ethyl-2-thioxo-imidazolidin-4-one l-Ethyl-3-(2-tolyl)-2-thioxo-imidazolidin-4-one

3-(2-Chloro-6-methylphenyl)-l-ethyl-2-thioxo-imidazolidin-4-one l-Ethyl-3-(5-fluoro-2-methylphenyl)-2-thioxo-imidazolidin-4-one 3 -(2,6-Diisopropylphenyl)- 1 -ethyl-2-thioxo-imidazolidin-4-one l-E yl-2-thioxo-3-(2-trifluoromethylphenyl)-imidazolidin-4-one l-Emyl-3-(2-ethyl-6-πi€thylphenyl)-2-thioxcr-irnidazolidin-4-one

3-(2-Chloro-4-methylphenyl)-l-ethyl-2-thioxo-imidazolidin-4-one 3-(2,4-Dichlorophenyl)-l-ethyl-2-thioxo-imidazolidin-4-one 3-(2,4-Dimethylphenyl)- 1 -ethyl-2-thioxo-imidazolidin-4-one 3-(2,5-Dimethylphenyl)-l-ethyl-2-thioxo-imidazolidin-4-one l-Ethyl-2-thioxo-3-(2,4,5-trimethylphenyl)-imidazolidin-4-one l-Ethyl-3-(2-isopropylphenyl)-2-thioxo-imidazolidin-4-one l-Ethyl-3-(2-ethylphenyl)-2-unoxo-imidazolidin-4-one 3-(5-Chloro-2-methylphenyl)- 1 -phenyl-2-thioxo-imidazoIidin-4-one 3-(5-Chloro-2-methylphenyl)-l-isopropyl-2-thioxo-imidazolidin-4-one 3-(2,6-Dimethylphenyl)-l-isopropyl-2-thioxo-imidazolidin-4-one

3-(2-Ethyl-6-methylphenyl)-l-isopropyl-2-thioxo-imidazolidin-4-one l-Butyl-3-(4-fluorophenyl)-2-thioxo-imidazolidin-4-one l-Allyl-3-(2,6-dimethylphenyl)-2-thioxo-imidazolidin-4-one 3-(2,6-Dimethylphenyl)-l-(prop-2-ynyl)-2-thioxo-imidazolidin-4-one 3-(3-Chloro-4-methylphenyl)-l-methyl-2-thioxo-imidazolidin-4-one

3-(2-Ethylphenyl)- 1 -methyl-2-thioxo-imidazolidin-4-one l-Methyl-3-(2-isopropylphenyl)-2-thioxo-imidazolidin-4-one 3-(4-t-Butylphenyl)- 1 -methyl-2-thioxo-imidazolidin-4-one l-Allyl-3-(5-chloro-2-methylphenyl)-2-thioxo-imidazolidin-4-one 3-(5-Chloro-2-methylphenyl)- 1 -(prop-2-ynyl)-2-thioxo-imidazolidin-4-one l-Ethyl-3-(2-ethyl-6-isopropylphenyl)-2-thioxo-imidazolidin-4-one. A preferred use of the compounds of formula I or method of treatment using the compounds is for increasing HDL cholesterol concentration in the blood of a mammal, by administering to said mammal an amount of a substituted 2-thioxo-imidazolidin-4- one as herein defined, sufficient to increase that HDL cholesterol concentration, and this represents further aspects of the present invention.

The compounds of the invention can be prepared readily according to the following reaction scheme or modification thereof using readily available starting materials, reagents and conventional synthetic procedures. It is also possible to make use of variants of these process steps, which in themselves are known to and well within the preparatory skill of the medicinal chemist. In the following reaction scheme, R is hydrogen or alkyl of 1 to 6 carbon atoms and X is a halogen.

(2b)

(1) (2a)

N-Substituted amino acids (2a) were prepared by reacting the corresponding α- halo acids (1) with the appropriate amines (excess). The reaction was carried out either neat or in water at ambient temperature for 18 hours. One equivalent of the amine scavenges the hydrohalide formed during the alkylation forming the amine hydrohalide (2b) as a side product. The N-alkyl amino acids (2a) were either purified by crystallization from an appropriate solvent, or reacted with the isothiocyanates as crude product mixtures containing the amine hydrohalide salt. Reaction of 2a with isothiocyanates is carried out in chloroform or methylene chloride in the presence of a base such as triethyl amine. The mixture is heated at reflux for 3 to 18 hours. The reaction affords either the thiourea (3a) or the thiohydantoin (4) direcdy (depending on the nature of R ). Cyclization of 3a to the thiohydantoin (4) is accomplished by refluxing in ethanol for 2 to 3 hours in the presence of base (triethyl amine). In the case of reacting d e crude product mixture (2a & 2b) with isothiocyanates, the thiourea (3b) is formed as a side product along with 4. Purification of 4 was achieved by 1) fractional crystallization, 2) flash chromatography, 3) extracting 3b in 2N hydrochloric acid or 4) precipitating 3b as its hydrochloride salt from an appropriate solvent such as ethyl acetate or diethyl ether. This invention also provides pharmaceutical compositions comprised of uie 2- thioxo imidazolidin-4-one derivatives either alone or in combination with excipients (i.e. pharmaceutically acceptable materials with no pharmacological effects). Such compositions are useful in the treatment of atherosclerotic conditions such as dyslipoproteinemias and coronary heart disease, in that they increase the blood serum high density lipoprotein concentration of mammals treated with the compounds.

The precise dosage to be employed depends upon several factors including the host, whether in veterinary medicine or human medicine, the nature and severity of the condition being treated, the mode of administration and the particular active substance employed. The compounds may be administered by any conventional route, in particular enterally, preferably orally in the form of tablets or capsules. Administered compounds can be in the free form or pharmaceutically acceptable salt form as appropriate, for use as a pharmaceutical, particularly for use in the prophylactic or curative treatment of atherosclerosis and sequelae (angina pectoris, myocardial infarction, arrhythmias, heart failure, kidney failure stroke, peripheral arterial occlusion, and related disease states). These measures will slow the rate of progress of the disease state and assist the body in reversing the process direction in a natural manner.

Any suitable carrier known to the art can be used to prepare the pharmaceutical compositions. In such a composition, the carrier may be a solid, liquid or mixture of a solid and a liquid. Solid compositions include powders, tablets and capsules. A solid carrier can be one or more substances which may also act as a flavoring agent, lubricant, solubilizer, suspending agent, binder, or tablet disintegrant. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets the active ingredient is mixed with a carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, hydroxymethyl cellulose, sodium carboxymethyl cellulose, a low melting wax, cocoa butter, and the like. Encapsulating materials may also be employed with the compounds of this invention, and the term "composition" is intended to include the active ingredient in combination with an encapsulating material as a formulation, with or without other carriers. Cachets may also be used in the delivery of the anti-atherosclerotic medicament of this invention. Sterile liquid compositions include solutions, suspensions, emulsions, syrups and elixirs. The compounds of this invention may be dissolved or suspended in the pharmaceutically acceptable carrier, such as sterile water, sterile organic solvent or a mixture of both. Preferably the liquid carrier is one suitable for parental injection. Where the compounds are sufficiendy soluble they can be dissolved directly in normal saline with or without the use of suitable organic solvents , such as propylene glycol or polyethylene glycol. If desired, dispersions of the finely divided compounds can be made-up in aqueous starch or sodium carboxymethyl cellulose solution, or in a suitable oil, such as arachis oil. Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by intramuscular, intraperitoneal or subcutaneous injection. In many instances a liquid composition form may be used instead of the preferred solid oral method of administration.

It is preferred to prepare unit dosage forms of the compounds for standard administration regimens. In this way, the composition can be subdivided readily into smaller doses at the physicians direction. For example, unit dosages may be made up in packeted powders, vials or ampoules and preferably in capsule or tablet form. The active compound present in these unit dosage forms of the composition may be present in an amount of from about one gram to about fifteen grams or more, for single or multiple daily administration, according to the particular need of the patient. The daily dose of active compound will vary depending upon the route of administration, the size, age and sex of the patient, the severity of the disease state, and the response to the therapy as traced by blood analysis and the patients recovery rate. By initiating the treatment regimen with a minimal daily dose of about one gram, the blood levels of HDL and the patients symptomatic relief analysis may be used to determine whether a larger dose is indicated. Based upon the data presented below, the projected daily dose for both human and veterinary use will be from about 10 to about 200 milligrams/kilogram per day. However, in general, satisfactory results are indicated to be obtained at daily dosages in the range of from 400 milligrams to about 2000 milligrams, conveniendy administered in divided doses two to four times a day. The ability of the compounds of this invention to increase blood serum HDL levels was established by the following standard experimental procedure for determination of HDL cholesterol:

Male Sprague-Dawley rats weighing 200-225 g are housed two per cage and fed Purina Rodent Chow Special Mix 5001-S supplemented with 0.25 % cholic acid and 1.0 % cholesterol and water ad libitum for 8 days. Each test substance is administered to a group of six rats fed the same diet with the test diet mixed in as 0.005 - 0.1 % of the total diet. Body weight and food consumption are recorded prior to diet administration and at termination. Typical doses of the test substances are 5 - 100 mg/kg/day. At termination, blood is collected from anesthetized rats and the serum is separated by centrifugation. Total serum cholesterol is assayed using the Sigma Diagnostics enzymatic kit for the determination of cholesterol, Sigma Procedure No. 352, modified for use with ninety-six well microtiter plates. After reconstitution with water the reagent contains 300 U/1 cholesterol oxidase, 100 UΛ cholesterol esterase, 1000 U/1 horse radish peroxidase, 0.3 mmoles/l 4-aminoantipyrine and 30.0 mmoles/l p-hydroxybenzenesulfonate in a pH 6.5 buffer. In the reaction cholesterol is oxidized to produce hydrogen peroxide which is used to form a quinoneimine dye. The concentration of dye formed is measured spectrophotometrically by absorbance at 490 nm after incubation at 25C for 30 minutes. The concentration of cholesterol was determined for each serum sample relative to a commercial standard from Sigma.

HDL cholesterol concentrations in serum are determined by separation of lipoprotein classes by fast protein liquid chromatography (FPLC) by a modification of the method of Kieft et al., J. Lipid Res.. 2 (1991) 859-866. 25 ul of serum is injected onto Superose 12 and Superose 6 (Pharmacia), in series, with a column buffer of 0.05 M Tris (2-amino-2-hydroxymethyl-l,3-propanediol) and 0.15 M sodium chloride at a flow rate of 0.5 ml/min. The eluted sample is mixed on line with Boehringer-Mannheim cholesterol reagent pumped at 0.2 ml/min. The combined eluents are mixed and incubated on line through a knitted coil (Applied Biosciences) maintained at a temperature of 45C. The eluent is monitored by measuring absorbance at 490 nm and gives a continuous absorbance signal proportional to the cholesterol concentration. The relative concentration of each lipoprotein class is calculated as the per cent of total absorbance. HDL cholesterol concentration, in serum, is calculated as the per cent of total cholesterol as determined by FPLC multiplied by the total serum cholesterol concentration.

Test compounds were administered at a dose of 100 mg/kg. The duration of treatment was eight days. The compounds of the present invention increase HDL cholesterol concentrations as summarized in Table I:

Table I

Compound of HDL Cholesterol Level Example Increase (%)

1 159

2 57

3 29

4 39

5 150

6 101

7 202

8 112

9 89

10 141

11 203

12 84

13 222

14 203

15 92

16 132

17 142

18 59

19 39

20 265 Table I (Continued)

Compound of HDL Cholesterol Level Example Increase (%)

21 180

22 26

23 95

24 157

25 163

26 65

27 222

28 112

29 54

30 115

31 167

32 112

33 66

34 49

35 98

36 30

37 49

38 83

39 124

40 112

41 202

42 237

43 78

44 39

45 127 Table I (Continued)

Compound of HDL Cholesterol Level Example Increase (%)

46 146

47 24

48 64

49 52

50 77

51 88

52 100

53 47

54 71

55 87

56 53

57 183

58 62

59 177

60 74

61 325

62 204

63

The following examples are presented to illustrate the production of representative compounds useful in the metiiod of this invention, rather than as a limit to the scope of applicant's invention:

EXAMPLE 1

3-(5-Chloro-2-methvlphenvn.l -methvl-2.thioxo-imiday.olidin-4-one

A mixture of sarcosine ethyl ester hydrochloride (7.68 g), 5-chloro-2- methy Iphenyl-isothiocyanate (9.18 g), triethyl amine (12 g) and chloroform (200 mL) was heated at reflux for 5 hours. The mixture was cooled to ambient temperature, washed with IN HCl (2x200 mL), then with water (200 mL) The organic phase was evaporated to dryness. The residue was crystallized from ethanol to give the tide compound (9.2 g) as a tan solid, m.p. 132-134° C. Anal. Calcd. for Cl l Hi i Cl N2 O

S: C, 51.87; H, 4.35; N,11.00. Found: C, 51.79; H, 4.12; N, 10.73. Mass spectrum (EI, M.+) m/z 254/256.

EXAMPLE 2

3-Benzhvdrvl-l-methvl-2-thioxn-imidazolidin-4-one

The title compound was prepared by the procedure described in Example 1 using 11.25 g of benzhydryl-isothiocyanate, 7.68 g of sarcosine eu yl ester hydrochloride, 12 g of triethyl amine, and 200 mL of chloroform. The title compound was obtained (7.40 g) as an off-white solid, m.p. 139-141° C. Anal. Calcd. for Cπ Hi6 N2 O S: C, 68.89; H, 5.44; N, 9.45. Found: C, 68.92; H, 5.43; N, 9.58. Mass spectrum (EI, M.+) m/z 296.

EXAMPLE 3

1.Methvl-3-(nvridin-3.vn-2-thioxo-imidazolidin-4-one

A mixture of sarcosine ethyl ester hydrochloride (7.68 g), pyridin-3-yl- isothiocyanate (6.8 g), triethyl amine (10.1 g) and chloroform (200 mL) was heated at reflux for 3.5 hours. The solvent was evaporated. The residue was dissolved in ethyl acetate (300 mL) and washed with water (2x200 mL). The organic phase was dried over anhydrous magnesium sulfate. The solvent was evaporated. Crystallization from ethyl acetate afforded the title compound (4.1 g) as an off-white solid, m.p. 149-151° C. Anal. Calcd. for Co H9 N3 O S: C, 52.16; H, 4.38; N, 20.28. Found: C, 52.16;

H, 4.05; N, 20.06. Mass spectrum (EI, M.+) m/z 207.

EXAMPLE 4 3.(5-Chloro.2-methoxvDhenvn.1.methvl-2.thioxo-imidazolidin-4-one

A mixture of sarcosine ethyl ester hydrochloride (7.68 g), 5-chloro-2- methoxyphenyl-isothiocyanate (10.0 g), triethyl amine (10.0 g) and chloroform (150 mL) was heated at reflux for 4.5 hours. The mixture was cooled to ambient temperature. The precipitated solid was collected, washed with chloroform and air dried to give the tide compound (11.8 g) as an off-white solid, m.p. 245-247° C. Anal. Calcd. for Cn Hπ Cl N2 O2 S: C, 48.80; H, 4.10; N,10.35. Found: C, 48.42; H,

3.96; N, 10.33. Mass spectrum (EI, M.+) m/z 270.

EXAMPLE S -r3-Chlor .2-methvlDhenvh- l-methvl.2-thiov(>-imida7olidin-4-onp

The title compound was prepared by the procedure described in Example 1 using 13.2 g of 3-chloro-2-methylphenyl-isothiocyanate, 11.0 g of sarcosine ethyl ester hydrochloride, 25 g of triethyl amine, and 300 mL of chloroform. Crystallization from diethyl ether afforded the tide compound (15.2 g) as a tan solid, m.p. 122-124° C.

Anal. Calcd. for Cn Hi 1 Cl N2 O S: C, 51.87; H, 4.35; N, 11.00. Found: C, 51.96;

H, 4.21 ; N, 11.05. Mass spectrum (EI, M.+) m/z 254/256.

EXAMPLE fi 3-ι3-Chloro-4-methylDhenyl ι-l-methyl-2-thioxo-irnidazo!idin-4-one

The tide compound was prepared by the procedure described in Example 1 using 18.3 g of 3-chloro-4-methylphenyl-isothiocyanate, 15.3 g of sarcosine ethyl ester hydrochloride, 25 g of triethyl amine, and 300 mL of chloroform. Crystallization from ethyl acetate afforded the tide compound (14.5 g) as an off-white solid, m.p. 178-180°

C. Anal. Calcd. for Cn Hπ Cl N2 O S: C, 51.87; H, 4.35; N.11.00. Found: C,

51.89; H, 4.20; N, 10.95. Mass spectrum (+FAB, [M+HJ+) m/z 255/257.

EXAMPLE 7 3-r4.Chloro-2.methvlDhenvn- l-methvl-2.thioxo-imidazolidin-4-one

The tide compound was prepared by the procedure described in Example 1 using 9.18 g of 4-chloro-2-methylphenyl-isothiocyanate, 7.68 g of sarcosine ethyl ester hydrochloride, 12.0 g of triethyl amine, and 300 mL of chloroform. Crystallization from diethyl ether afforded the title compound (7.5 g) as an off-white solid, m.p. 113-

115° C. Anal. Calcd. for Cn Hn Cl N2 O S: C, 51.87; H, 4.35; N.l l.OO. Found: C,

51.72; H, 4.17; N, 10.88. Mass spectrum (EI, M.+) m/z 254/256. EXAMPLE ft

3-rindan-S-vh-1 -mfthvl-2.thioxo.imida7olidin-4.onp

The tide compound was prepared by the procedure described in Example 1 using 7.7 g of indan-5-yl-isothiocyanate, 6.7 g of sarcosine ethyl ester hydrochloride, 12 g of trieuiyl amine, and 300 mL of chloroform. Crystallization from ethyl acetate afforded uie tide compound (7.9 g) as a tan solid, m.p. 158-160° C. Anal. Calcd. for Cl3 Hi4 N2 O S: C, 63.39; H, 5.73; N.11.37. Found: C, 63.30; H, 5.81; N, 11.31. Mass spectrum (EI, M.⁺) m/z 246.

EXAMPLE 9

-l.r2-6.Diisonronvlnhenvh.l -methvI.2-thioxo-imida7olidin-4-on.

The tide compound was prepared by the procedure described in Example 1 using 8.3 g of 2,6-diisopropylphenyl-isothiocyanate, 5.8 g of sarcosine ethyl ester hydrochloride, 14.5 g of triethyl amine, and 200 mL of chloroform. Crystallization from diethyl edier/hexane mixture afforded the title compound (6.6 g) as a tan solid, m.p. 174-176° C. Anal. Calcd. for Ci6 H22 2 O S: C, 66.17; H, 7.63; N, 9.64. Found: C, 66.39; H, 7.63; N, 9.59. Mass spectrum (+FAB, [M+H]+) m/z 269/271.

EXAMPLE 10 -3.f2-Ethvl-6-isoproDvlDhenvn-l-methvl-2-thioxo-imidazolidin-4-one

The title compound was prepared by the procedure described in Example 1 using 10.25 g of 2-ethyl-6-isopropylphenyl-isoϋiiocyanate, 7.68 g of sarcosine ethyl ester hydrochloride, 14.8 g of triethyl amine, and 200 mL of chloroform. Crystallization from diediyl eΛer/hexane mixture afforded the tide compound (8.95 g) as a tan solid, m.p. 132-134° C. Anal. Calcd. for C15 H20 N2 O S: C, 65.18; H, 7.29; N, 10.13. Found: C, 65.11; H, 7.31; N, 10.05. Mass spectrum (PBEI, M.+ ) m/z 276. EX AMPLE 11

3.f2.Ethvl-6-methvlnhenvn.l-methvl.2-thioxo.imidazoHdin-4-one

The tide compound was prepared by d e procedure described in Example 1 using 8.9 g of 2-euiyl-6-meuiylphenyl-isouiiocyanate, 7.68 g of sarcosine ethyl ester hydrochloride, 12.5 g of trieuiyl amine, and 250 mL of chloroform. Crystallization from diethyl ether afforded die title compound (7.45 g) as a peach solid, m.p. 106-108° C. Anal. Calcd. for Ci3 Hi6 N2 O S: C, 62.87; H, 6.49; N, 11.28. Found: C, 62.52;

H, 6.61; N, 1 1.29. Mass spectrum (+ESI, [M+H]+) m/z 269/2 '1.

EXAMPLE 12 3-f2.Chloro-6-methvlDhenvn.l-methvl.2-thioxo-imida?.olidin-4-one

The tide compound was prepared by the procedure described in Example 1 using 9.2 g of 2-chloro-6-methylphenyl-isouiiocyanate, 7.68 g of sarcosine euiyl ester hydrochloride, 12 g of triethyl amine, and 200 mL of chloroform. Crystallization from ethanol afforded the title compound (7.1 g) as an orange solid (7.1 g), m.p. 142-145°

C. Anal. Calcd. for. Cn Hn Cl N2 O S: C, 51.87; H, 4.35; N,11.00. Found: C,

51.96; H, 4.26; N, 10.97. Mass spectrum (EI, M.+) m/z 254.

EXAMPLE 1 3-f2.Ethvlphenvn.l .methv».2-thioxo-imidazolidin.4-one

The tide compound was prepared by die procedure described in Example 1 using 16.3 g of 2-ethylphenyl-isothiocyanate, 15.3 g of sarcosine ethyl ester hydrochloride, 20.2 g of triethyl amine, and 300 mL of chloroform. The tide compound (20.4 g) was obtained as an off-white solid, m.p. 135-137° C. Anal. Calcd. for Cl2 Hi4 N2 O S: C, 61.51; H, 6.02; N,11.96. Found: C, 61.11; H, 5.92; N,

11.71. Mass spectrum 031, M.+) m/z 234. EXAMPLE 14 1.Methvl-3-r2-isoDroDvlDhenvh-2.thioxo.imidazolidin.4-one

The tide compound was prepared by d e procedure described in Example 1 using 14.2 g of 2-isopropylphenyl-isouiiocyanate, 12.29 g of sarcosine ethyl ester hydrochloride, 16.0 g of trieuiyl amine, and 200 mL of chloroform. Crystallization from diethyl ether afforded the title compound (15.9 g) as a peach solid, m.p. 129-131° C. Anal. Calcd. for C13 Hi6 N2 O S: C, 62.87; H, 6.49; N, 11.28. Found: C, 62.89; H, 6.38; N, 11.28. Mass spectrum (EI, M.+) m/z 248.

EXAMPLE S 3.r2.6-DichloroDhenvn-l-methvl-2-thioxo.imidazoiidin-4-one

The tide compound was prepared by the procedure described in Example 1 using 14.28 g of 2,6-dichlorophenyl-isothiocyanate, 10.75 g of sarcosine etiiyl ester hydrochloride, 14.5 g of trieuiyl amine, and 200 mL of chloroform. Crystallization from diediyl euier afforded the tide compound (16.9 g) as a light peach solid, m.p.

207-209° C. Anal. Calcd. for ClO Hδ Cl2 N2 O S: C, 43.65; H, 2.93; N, 10.18.

Found: C, 43.57; H, 2.61; N, 10.14. Mass spectrum (EI, M.+) m/z 21 A.

EXAMPLE 16 3-f5-Chloro.2-methvlDhenvn-l-ethvl-2-thioxo-imidazolidin-4-one

2-Chloro acetic acid (27.5 g) was added portionwise while stirring to a 70% aqueous ethyl amine solution (500 mL). The addition was carried over a period of 30 minutes. The mixture was stirred at ambient temperature for 18 hours. The mixture was tiien evaporated to a viscous oily residue (55 g). The crude product consisted of a 1:1 mixture of N-etfiyl glycine and ediyl amine hydrochloride. This product mixture was usedwithout further purification for d e preparation of the tide compound, in the next paragraph, and for preparation of the title compounds described in Example 17 through Example 42 and in Example 58.

A mixture of die crude N-ethyl glycine (9.23 g), 5-chloro-2-methylphenyl- isod iocyanate (9.18 g), triethyl amine (10 g) and chloroform (250 mL) was heated at reflux for 18 hours. The solvent was evaporated. The residue was dissolved in ethyl acetate (400 mL) and water (300 mL). The organic phase was washed with IN HCl (2x300 mL), tiien evaporated to dryness. Purification was achieved dirough crystallization from ethanol. The tide compound (7.6 g) was obtained as a light pink solid, m.p. 152-154° C. Anal. Calcd. for. C12 H13 Cl N2 O S: C, 53.63; H, 4.88; N,

10.42. Found: C, 53.36; H, 4.79; N, 10.35. Mass spectrum (EI, M.+) m/z 268/270.

EXAMPLE 17 3.⁽2.fi.nichloroohenvn-l-ethvl-2-thioxo.imida7oHdin-4-one

The tide compound was prepared by die procedure described in Example 16 using 10.2 g of 2,6-dichlorophenyl-isothiocyanate, 7.4 g of N-eύiyl glycine, 10 g of trieuiyl amine, and 250 mL of chloroform. Purification was achieved through crystallization from ethanol. The tide compound (6.5 g) was obtained as a tan solid, m.p. 170-172° C. Anal. Calcd. for. Cn Hio Cl2 N2 O S: C, 45.69; H, 3.48; N,

9.69. Found: C, 45.53; H, 3.19; N, 9.62. Mass spectrum (EI, M.+) m/z 288/290/292.

EXAMPLE 1ft 1 -Ethvl-3-(4-nuorθDhenvl)-2-thioxo-imidazolidin-4-one

The tide compound was prepared by d e procedure described in Example 16 using 7.65 g of 4-fluorophenyl-isothiocyanate, 9.32 g of N-etivyl glycine, 10 g of triethyl amine, and 250 mL of chloroform. Purification was achieved through crystallization from ethanol. The tide compound (6.6 g) was obtained as a pink solid, m.p. 149-151° C. Anal. Calcd. for. C11 H11 F N2 O S: C, 55.45; H, 4.65; N.1 1.76.

Found: C, 55.31; H, 4.51; N, 10.82. Mass spectrum (EI, M.+) m/z 238.

EXAMPLE 19 3.(5.Chloro-2-methoxvDhenvn-l-ethvl-2-thioxo-imidazolidin-4.one

A mixture N-ethyl glycine (9.2 g), 5-chloro-2-methoxyphenyl-isothiocyanate (10 g), triediylamine (10.1 g), meύiylene chloride (150 mL) was heated at reflux for 3.5 hours. The mixture was evaporated to dryness. The residue collected, washed witii hot edianol and dried. Tide compound (7.6 g) was obtained as a creamy solid, m.p. 171-174° C. Anal. Calcd. for. Ci2 H13 Cl N2 O2 S: C, 50.61; H, 4.60; N, 9.84.

Found: C, 50.33; H, 4.50; N, 9.69. Mass spectrum (EI, M.+) m/z 284/286.

EXAMPLE 20

1.Ethvl-2-thioxo-3-(4-trinuoromethoxvnhenvn-imidazolidin-4-nne

The tide compound was prepared by the procedure described in Example 19 using 9.2 g of N-ethyl glycine, 10.9 g of 4-trifluoromethoxyphenyl-isodιiocyanate, 10.1 g of triethylamine, and 150 mL of methylene chloride. Purification was achieved by flash chromatography on silica gel (methylene chloride). Tide compound (4.6 g) was obtained as a creamy solid, m.p. 116-119° C. Anal. Calcd. for. C12 Hn F3 N2 O2 S: C, 47.37; H, 3.64; N, 9.21. Found: C, 47.20; H, 3.50; N, 9.13. Mass spectrum (EI, M.+) m/z 304.

EXAMPLE 21

3.r2.6.Dimethvlphenvn-l -ethvl-2-thioxo-imidazolidin-4-one

The tide compound was prepared by the procedure described in Example 19 using 9.2 g of N-ethyl glycine, 8.2 g of 2,6-dimethylphenyl-isodιiocyanate, 10.1 g of triethylamine, and 150 mL of metiiylene chloride. Purification was achieved through crystallization from ethanol. Title compound (2.3 g) was obtained as a white solid (2.3 g). m.p. 128-131° C. Anal. Calcd. for. C13 Hi6 N2 O S: C, 62.87; H, 6.49; N,

11.28. Found: C, 62.83; H, 6.50; N, 11.25. Mass spectrum (EI, M.+) m/z 248.

EXAMPLE 22 1.Ethvl-3.t4-fluorohenzvh.2.thioxo.imidazolidin-4-one

The tide compound was prepared by d e procedure described in Example 19 using 9.2 g of N-ethyl glycine, 8.4 g of 4-fluorobenzyl-isothiocyanate, 10.1 g of triethylamine, and 150 mL of metiiylene chloride. Purification was achieved through crystallization from ethyl acetate/hexane mixture. Tide compound (4.85 g) was obtained as a white solid, m.p. 73-76° C. Anal. Calcd. for. C12 Hi 3 F N2 O S: C, 57.12; H, 5.19; N, 11.10 Found: C, 56.97; H.5.15; N, 11.06. Mass spectrum (EI, M.+) m/z 252.

EXAMPLE 23 1 -EthvI-3-isobutvl-2-thioxo-imida7.olidin-4.nnP

The tide compound was prepared by d e procedure described in Example 19 using 9.2 g of N-etiryl glycine, 5.7 g of isobutyl-isothiocyanate, 10.1 g of triethylamine, and 150 mL of metiiylene chloride. Purification was achieved by flash chromatography on silica gel (methylene chloride). Titie compound (2.3 g) was obtained as an oil. Anal. Calcd. for. C9 Hi6 N2 O S: C, 53.97; H, 8.05; N, 13.99.

Found: C, 54.01; H, 8.21; N, 14.00. Mass spectrum (EI, M.+) m/z 200.

EXAMPLE 24 3-f2-ChloroDhenvn-l-ethvl-2-thioxo-imidazolidin-4-one

The tide compound was prepared by die procedure described in Example 19 using 9.2 g of N-ethyl glycine, 8.48 g of 2-chlorophenyl-isouiiocyanate, 10.1 g of triethylamine, and 150 mL of methylene chloride. Purification was achieved through crystallization from ethanol. Tide compound (3.85 g) was obtained as an orange solid, m.p. 142-145° C. Anal. Calcd. for. Cn Hn Cl N2 O S: C, 51.87; H, 4.35; N ,

11.00. Found: C, 51.96; H, 4.26; N, 10.97. Mass spectrum (EI, M.+) m/z 254.

EXAMPLE 25 1 -Ethvl-3-^2-tolvh-2-thioxo-imidazolidin-4-one

The tide compound was prepared by die procedure described in Example 19 using 9.2 g of N-ethyl glycine, 7.4 g of 2-tolyl-isothiocyanate, 10.1 g of triethylamine, and 150 mL of metiiylene chloride. Purification was achieved through crystallization from edianol. Title compound (3.6 g) was obtained as a creamy solid, m.p. 105-108°

C. Anal. Calcd. for. C12 H14 N2 O S: C, 61.51; H, 6.02; N.11.93. Found: C, 61.22;

H, 5.96; N, 11.89. Mass spectrum (EI, M.+) m/z 234. EXAMPLE 26 1.Ethvl-3.(naDhthalen-2-vn-2-thioxo.imidazolidin-4-nne

The tide compound was prepared by the procedure described in Example 19 using 9.2 g of N-ediyl glycine, 9.3 g of 2-naphthyl-isothiocyanate, 10.1 g of triethylamine, and 150 mL of metiiylene chloride. Purification was achieved dirough crystallization from ethanol. Title compound (4.7 g) was obtained as a light pink solid, m.p. 156-159° C. Anal. Calcd. for. C15 H14 N2 O S: C, 66.64; H, 5.22; N, 10.36

Found: C, 66.69; H,5.24; N, 10.42. Mass spectrum (EI, M.+) m/z 270.

EXAMPLE 27 3.r2.Chloro.6-methvlDhenvn-l -ethvl-2.thioxo-imidazolidin-4-one

The tide compound was prepared by the procedure described in Example 19 using 9.2 g of N-ethyl glycine, 9.1 g of 2-chloro-6-methylphenyl-isothiocyanate, 10.1 g of triethylamine, and 150 mL of methylene chloride. Purification was achieved by flash chromatography on silica gel (methylene chloride). Crystallization from ethanol afforded the tide compound (5.4 g) as a creamy solid, m.p. 124-126° C. Anal. Calcd. for. C12 H13 Cl N2 O S: C, 53.63; H, 4.87; N, 10.42. Found: C, 53.43; H, 4.79; N, 10.28. Mass spectrum (EI, M.⁺) m/z 268/270.

EXAMPLE 2ft

1 -Ethvl-3-f5-fluoro-2-methvlDhenvn-2-thioxo.imidazolidin-4-one

A mixture of the crude N-ediyl glycine (11.5 g), 5-fluoro-2-methylphenyl- isothiocyanate (10.42 g), triethyl amine (12.5 g) and chloroform (300 mL) was heated at reflux for 6 hours. The solvent was evaporated. The residue was dissolved in ethyl acetate (500 mL) and washed widi water (500 mL). The organic phase was evaporated to dryness. The residue was dissolved in ethanol (50 mL), then diluted with dietiiyl ether (200 mL). The solution was saturated widi hydrogen chloride. The mixture was filtered. The solid was discarded. The filtrate was evaporated to dryness. The residue was dissolved in diethyl ether (300 mL) and washed with water (200 mL). The organic phase was dried over anhydrous sodium sulfate and evaporated to dryness. Crystallization from ethanol afforded the title compound (6.5 g) as a pink solid, m.p. 98-100° C. Anal. Calcd. for. Ci2 H13 F N2 O S: C, 57.13; H, 5.19; N, 11.10. Found: C, 56.88; H, 5.17; N, 11.05. Mass spectrum (EI, M.+) m/z 252.

EXAMPLE 29 3-t2.6-DiisoDropvlDhenvn.1.ethvl-2.thioxo-iιnidayolidin.4.nnp

The titie compound was prepared by the procedure described in Example 16 using 21.9 g of 2,6-diisopropylphenyl-isothiocyanate, 18.4 g of N-ethyl glycine, 20.2 g of triethyl amine, and 300 mL of chloroform. Purification was achieved through crystalUzation from ethanol. The title compound (8.2 g) was obtained as light yellow solid, m.p. 159-161° C. Anal. Calcd. for. C17 H24 N2 O S: C, 67.07; H, 7.94; N ,

9.20. Found: C, 66.92; H, 8.03; N, 9.13. Mass spectrum (PBEI, M.+) m/z 304.

EXAMPLE 30 1 -Ethvl.2-thioxo-3-f2-triflιιoromethvlnhenvn-imidazolidin.4-one.

The tide compound was prepared by the procedure described in Example 19 using 9.2 g of N-ethyl glycine, 10.2 g of 2-(trifluoromethyl)-phenyl-isothiocyanate, 10.1 g of triethylamine, and 150 mL of methylene chloride. The residue was further purified by flash chromatography on silica gel (methylene chloride). Crystallization from ethanol afforded d e titie compound (2.7 g), m.p. 82-85° C. Anal. Calcd. for. Cl2 H F3 N2 O S: C, 50.00; H, 3.85; N.9.72. Found: C, 50.00; H, 3.61; N, 9.61.

Mass spectrum (EI, M.⁺) m/z 288.

EXAMPLE 31

1-Ethvl-3-t2-ethvl-6-isoDronvlphenvl ι-2-thioxo-imidazolidin-4-one

The tide compound was prepared by d e procedure described in Example 28 using 20.5 g of 2-ethyl-6-isopropylphenyl-isouiiocyanate, 18.4 g of N-ethyl glycine, 20.2 g of triethyl amine, and 300 mL of chloroform. Purification was achieved by flash chromatography on silica gel (5-10 % ethyl acetate in hexane). CrystalUzation from diethyl ether/hexane afforded pure title compound (7.5 g) as a white solid, m.p. 77-79° C. Anal. Calcd. for. Ci6 H22 N2 O S: C, 66.17; H, 7.64; N, 9.65. Found: C, 66.12; H, 7.77; N, 9.69. Mass spectrum (EI, M.⁺) m/z 290.

EXAMPLE 32 1 -Ethvl.3-(2-ethvl-6-methvlphenvn-2-thioxo-imidazolidin-4-nnp

The tide compound was prepared by the procedure described in Example 28 using 17.7 g of 2-ethyl-6-methylphenyl-isothiocyanate, 18.4 g of N-ethyl glycine, 20.2 g of trieuiyl amine, and 300 mL of chloroform. The residue was further purified by flash chromatography on silica gel (20 % etfiyl acetate in hexane).The title compound was obtained (8.6 g) as a light peach solid, m.p. 82-84° C. Anal. Calcd. for. C14 H s N2 O S: C, 64.09; H, 6.92; N, 10.68. Found: C, 64.27; H, 7.04; N, 10.60. Mass spectrum (EI, M.⁺) m/z 262.

EXAMPLE 33

3-(2-Chloro-4-methvlphenvn-l -ethvl-2-thioxo-imidazolidin-4-one

The tide compound was prepared by the procedure described in Example 28 using 18.3 g of 2-chloro-4-methylphenyl-isothiocyanate, 18.4 g of N-etivyl glycine, 20.2 g of triethyl amine, and 300 mL of chloroform. Crystallization from ethyl acetate afforded the titie compound (5.8 g) as a peach solid, m.p. 126-128° C. Anal. Calcd. for. C12 H13 Cl N2 O S: C, 53.63; H, 4.88; N, 10.42. Found: C, 53.50; H, 4.76; N,

10.28. Mass spectrum (+FAB, [M+H]+) m/z 269/271.

Example 34

1 -Ethvl-3-ri -r4-fluorophenvn-ethvn-2-thioxo-iιrιida7.nlidin-4-one

The tide compound was prepared by the procedure described in Example 16 using 18.1 g of l-(4-fluorophenyl)-ethyl-isothiocyanate, 18.4 g of N-ethyl glycine, 20.2 g of triethyl amine, and 300 mL of chloroform. Crystallization from ethyl acetate afforded die tide compound (8.8 g) as a Ught yellow solid, m.p. 93-95° C. Anal.

Calcd. for. C13 H15 F N2 O S: C, 58.63; H, 5.68; N, 10.52. Found: C, 58.69; H,

5.64; N, 10.58. Mass spectrum (EI, M.+) m/z 266. EXAMPLE 3ff

3.r2.4-nichlorophenvl _l-l-ethvl-2-thioxo.imida7.olidin-4-nne

The tide compound was prepared by the procedure described in Example 16 using 20.4 g of 2,3-dichlorophenyl-isothiocyanate, 18.4 g of N-ethyl glycine, 20.2 g of triethyl amine, and 300 mL of chloroform. Purification was achieved by flash chromatography on silica gel (20 % etiiyl acetate in hexane) The tide compound (8.8 g) was obtained as a light peach solid, m.p. 144-146° C. Anal. Calcd. for. Cn Hio Cl2 N2 O S: C, 45.69; H, 3.49; N, 9.69. Found: C, 45.81; H, 3.40; N, 9.58. Mass spectrum (CI, [M+H]+) m/z 289/291/293.

EXAMPLE 36 1 -Ethvl-3-phenethvl-2-thioxo-imida/olidin-4-one

The tide compound was prepared by the procedure described in Example 16 using 16.3 g of phenethyl-isothiocyanate, 18.4 g of N-ethyl glycine, 20.2 g of trieuiyl amine, and 300 mL of chloroform. Purification was achieved by flash chromatography on silica gel (20 % ethyl acetate in hexane) The title compound (15.0 g) was obtained as an off-white solid, m.p. 66-68° C. Anal. Calcd. for. C13 Hi6 N2 O S: C, 62.87; H,

6.49; N, 11.28. Found: C, 63.03; H, 6.49; N, 11.32. Mass spectrum OEl, M.+) m/z 248.

EXAMPLE 37 3-(2.3-nimethvlnhenvn-l-ethvl-2-thioxo-imidazolidin-4-one

The tide compound was prepared by tiie procedure described in Example 16 using 16.3 g of 2,3-dimethylphenyl-isothiocyanate, 18.4 g of N-ethyl glycine, 20.2 g of triethyl amine, and 250 mL of chloroform. Crystallization from ethanol afforded the title compound (10.3 g) as a light pink solid, m.p. 120-121° C. Anal. Calcd. for. C13 Hi6 N2 O S: C, 62.87; H, 6.49; N, 11.28. Found: C, 62.72; H, 6.44; N, 11.47. Mass spectrum (EI, M.⁺) m/z 248. EXAMPLE 38 3-f2.4-DimethvlDhenvn-l-ethvl-2-thioxo-imida7.olidin-4.one

The tide compound was prepared by the procedure described in Example 16 using 16.3 g of 2,4-dimethylphenyl-isothiocyanate, 18.4 g of N-ediyl glycine, 20.2 g of triethyl amine, and 250 mL of chloroform. CrystalUzation from ethanol afforded the title compound (10.8 g) as a light peach solid, m.p. 161-162° C. Anal. Calcd. for. C13 Hi6 N2 O S: C62.87; H, 6.49; N, 11.28. Found: C, 62.63; H, 6.45; N, 1 1.17. Mass spectrum (EI, M.⁺) m/z 248.

EXAMPLE 39 3. .->-nimethvlDhenvn-l-ethvl-2-thioxo-imida7 lidin-4-one

The tide compound was prepared by the procedure described in Example 16 using 16.3 g of 2,5-dimedιylphenyl-isothiocyanate, 18.4 g of N-ethyl glycine, 20.2 g of triethyl amine, and 250 mL of chloroform. Crystallization from ethyl acetate afforded the tide compound (10.6 g) as an off-white solid, m.p. 176-178° C. Anal. Calcd. for.

C13 Hi6 N2 O S: C62.87; H, 6.49; N, 11.28. Found: C, 62.70; H, 6.46; N, 11.27.

Mass spectrum (EI, M.+) m/z 248.

EXAMPLE 40 1-Ethvl-2-thioxo-3-(2.4.5-trimethvlDhenvl)-imidazolidin-4-one

The tide compound was prepared by d e procedure described in Example 16 using 17.7 g of 2,4,5-trimethylphenyl-isothiocyanate, 18.4 g of N-ethyl glycine, 20.2 g of trieuiyl amine, and 250 mL of chloroform. Crystallization from ethanol afforded d e tide compound (15.3g) as an off-white solid, m.p. 162-164° C. Anal. Calcd. for.

Cl4 Hi8 N2 O S: C64.09; H, 6.92; N, 10.68. Found: C, 64.21; H, 6.93; N, 10.80.

Mass spectrum (EI, M.⁺) m/z 262. EXAMPLE 41

1 -Ethvl-3-f2-isoDroDvlDhenvl)-2-thioxo-imidazolidin.4-onp

The tide compound was prepared by d e procedure described in Example 16 using 15.42 g of 2-isopropylphenyl-isothiocyanate, 16.05 g of N-ethyl glycine, 12 g of trieuiyl amine, and 200 mL of chloroform. Purification was achieved by flash chromatography on silica gel (5-20 % ethyl acetate in hexane) CrystalUzation from ethanol afforded the tide compound (9.8 g) as a white solid, m.p. 125-127° C. Anal. Calcd. for. Ci4 Hi8 N2 O S: C, 64.09; H, 6.91; N, 10.68. Found: C, 64.19 H, 6.93; N, 10.71. Mass spectrum (EI, M.+) m/z 262.

EXAMPLE 42

1 -Ethvl-3-f2-ethvlDhenvh-2-thioxo-imida7.olidin-4-one

The tide compound was prepared by die procedure described in Example 16 using 16.3 g of 2-edιylphenyl-isodιiocyanate, 18.4 g of N-ethyl glycine, 20.2 g of trieuiyl amine, and 200 mL of chloroform. Purification was achieved by flash chromatography on silica gel (5-10 % etiiyl acetate in hexane) Crystallization from diediyl etiier afforded the title compound (9.12 g) as a white solid, m.p. 71-73° C. Anal. Calcd. for. Ci3 Hi6 N2 O S: C62.87; H, 6.49; N, 11.28. Found: C, 62.81; H,

6.43; N, 11.17. Mass spectrum (EI, M.+) m/z 248.

EXAMPLE 43 3- S-Chloro-2-methvlnhenvl ι-1 -nhenvl-2-thioxo-imidazoIidin-4-one

A mixture of N-phenyl glycine etiiyl ester (8.95 g), 5-chloro-2-methylphenyl- isothiocyanate (9.18 g), and chloroform (200 mL) was heated at reflux for 24 hours.

The solvent was evaporated. The residue was crystallized from ethyl acetate/hexane mixture. The solid was collected and dried to give 17.2 g of 2-[3-(5-chloro-2- medιylphenyl)-l-phenyl-thioureido] -acetic acid ethyl ester as a white solid, m.p. 148-

150° C. Anal. Calcd. for. Ci8 H19 Cl N2 O2 S: C, 59.58; H, 5.28; N, 7.72. Found:

C, 59.79; H, 5.38; N, 7.65. Mass spectrum (EI, M.+) m/z 262/264. A mixture of 2-[3-(5-chloro-2-methylphenyl)-l-phenyl-thioureido]-acetic acid ethyl ester (9.5 g), triethyl amine (1 mL), and eti anol (150 mL) was heated at reflux for

2 hours. The mixture was concentrated to one-half volume and cooled to ambient temperature. The solid was coUected and air dried to give die tide compound (6.1 g) as an off-white solid, m.p. 168-170° C. Anal. Calcd. for. Ci6 H13 Cl N2 O S: C, 60.66;

H, 4.14; N, 8.84. Found: C, 60.81; H, 4.16; N, 8.81. Mass spectrum (EI, M.+) m/z 316/318.

EXAMPLE 44 3-f3-Chloro-2-methvlnhenvn- 1 -nhenvl-2-thioxo-imidazolidin.4-nne

A mixture of N-phenyl glycine etiiyl ester (8.95 g), 3-chloro-2-methylphenyl- isodiiocyanate (9.18 g), and chloroform (200 mL) was heated at reflux for 18 hours. The solvent was evaporated to dryness. The residue was mixed with ethanol (150 mL), and trieuiyl amine (3 mL). The mixture was heated at reflux for 3 hours. The solvent was evaporated. The residue was dissolved in ethyl acetate (300 mL) and washed with IN HCl (2x200 mL), then with water (200 mL). The organic phase was dried over anhydrous magnesium sulfate and evaporated to dryness. The residue was treated with diethyl etiier. The solid was coUected by filtration and air dried to give die title compound (5.3 g) as an off-white solid, m.p. 154-156° C. Anal. Calcd. for. Ci6 H13 Cl N2 O S: C, 60.66; H, 4.14; N, 8.84. Found: C, 60.48; H, 4.05; N, 8.76. Mass spectrum (+FAB, fM+H]+) m/z 317/319.

EXAMPLE 45 3-f5-Chloro-2-methvlDhenvn-l-isoDroDvl-2-thioxo-imidazolidin.4-one

2-Chloro acetic acid (69.0 g) was added portionwise while stirring to a isopropyl amine (431.5 g). The addition was carried over a period of 30 minutes. The mixture was stirred at ambient temperature for 18 hours. The excess isopropyl amine was evaporated leaving a viscous clear oil (182.0 g) which solidified upon standing. The crude product consisted of a 1:1 mixture of N-isopropyl glycine and isopropyl amine hydrochloride. This product mixture was used without further purification for die preparation of the titie compound, in d e next paragraph, and for preparation of the tide compounds described in Example 46 through Example 52. A mixture of the crude N-isopropyl glycine (21.2 g), 5-chloro-2-methylphenyl- isodiiocyanate (18.3 g), triethyl amine (21.0 g) and chloroform (300 mL) was heated at reflux for 4 hours. The solvent was evaporated. The residue was dissolved in ethyl acetate (400 mL) and water (300 mL). The organic phase was washed widi 2N HCl (2x300 mL), then witii water. The organic phase was dried over anhydrous magnesium sulfate and evaporated to dryness. CrystalUzation from ethanol afforded the title compound (15.4 g) as a peach solid, m.p. 142-144° C. Anal. Calcd. for. C13 H15 Cl N2 O S: C, 55.21; H, 5.35; N, 9.91. Found: C, 55.07; H, 5.20; N, 9.82. Mass spectrum (+FAB, [M+H]+) m/z 283/285.

EXAMPLE 46 3-(2.6-Dimethvlnhenvn-l-isopropvl-2-thioxo-iιnidazolidin-4-one

The title compound was prepared by d e procedure described in Example 45 using 16.3 g of 2,6-dimethylphenyl-isothiocyanate, 21.2g of N-isopropyl glycine, 21.0 g of tried yl amine, and 300 mL of chloroform. Crystallization from etiianol afforded the tide compound (12.9 g) as a white solid, m.p. 135-137° C. Anal. Calcd. for. C14 His N2 O S: C, 64.09; H, 6.92; N, 10.68. Found: C, 63.99; H, 6.72; N , 10.67. Mass spectrum (+FAB, [M+H]+) m/z 263.

EXAMPLE 47 3-f2-6-Diisopronvlnhenvn-1.isonropvl-2-thioxo-imida7.olidin-4-one

The tide compound was prepared by die procedure described in Example 45 using 21.9 g of 2,6-diisopropylphenyl-isotiύocyanate, 21.2 g of N-isopropyl glycine, 21.0 g of triethyl amine, and 300 mL of chloroform. CrystaUization from etiianol afforded d e tide compound (11.7 g) as a white solid, m.p. 175-177° C. Anal. Calcd. for. Ci8 H26 2 O S: C, 67.88; H, 8.23; N, 8.80. Found: C, 68.03; H, 8.09; N , 8.81. Mass spectrum (+FAB, [M+H]⁺) m/z 319. EXAMPLE 4ft

3.f4-Fliiorophenvl i-1-isopronvl-2-thioxo-imidazolidin-4-one

The title compound was prepared by the procedure described in Example 45 using 15.3 g of 4-fluorophenyl-isothiocyanate, 21.2 g of N-isopropyl glycine, 21.0 g of triethyl amine, and 300 mL of chloroform. CrystalUzation from ethanol afforded die tide compound (12.6 g) as a peach solid, m.p. 184-186° C. Anal. Calcd. for. Ci2 H13 F N2 O S: C, 57.12; H, 5.19; N, 11.10. Found: C, 56.98; H, 5.09; N, 11.06. Mass spectrum (+FAB, [M+H]+) m/z 253.

EXAMPLE 49 3-rindan-5-vl ι-l.isopropvl-2-thioxo-imidazolidin-4-one

The tide compound was prepared by d e procedure described in Example 45 using 17.5 g of indan-5-yl-isod iocyanate, 21.2 g of N-isopropyl glycine, 21.0 g of trieuiyl amine, and 300 mL of chloroform. Crystallization from ethanol afforded the title compound (9.9 g) as a white solid, m.p. 178-180° C. Anal. Calcd. for. C15 Hi8 N2 O S: C, 56.66; H, 6.61; N, 10.21. Found: C, 56.70; H, 6.67; N, 10.22. Mass spectrum (EI, M.⁺) m/z 21 A.

EXAMPLE 5ft 3.(2-Ethvl-6-methvlphenvn-l-isopropvl-2-thioxo-imidazolidin-4-one

The title compound was prepared by the procedure described in Example 45 using 17.7 g of 2-ethyl-6-methylphenyl-isothiocyanate, 21.2 g of N-isopropyl glycine,

21.0 g of triediyl amine, and 300 mL of chloroform. Crystallization from etiianol afforded die titie compound (13.0 g) as a Ught yellow solid, m.p. 132-134° C. Anal.

Calcd. for. C15 H20 N2 O S: C, 65.18; H, 7.29; N, 10.14. Found: C, 65.06; H,

7.37; N, 10.20. Mass spectrum (EI, M.+) m/z 276. EXAMPLE 51

3-(2-Ethvlphenvn-l -isoDroPvl-2-thioxo-imidflzoliriin.4.nnp

The tide compound was prepared by die procedure described in Example 45 using 16.3 g of 2-ethylphenyl-isothiocyanate, 21.2 g of N-isopropyl glycine, 21.0 g of trieuiyl amine, and 300 mL of chloroform. CrystaUization from diediyl ether afforded die tide compound (6.8 g) as a white solid, m.p. 103-105° C. Anal. Calcd. for. C14 Hi8 N2 O S: C, 64.09; H, 6.92; N, 10.68. Found: C, 64.08; H, 6.92; N, 10.62. Mass spectrum (EI, M.⁺) m/z 262.

EXAMPLE 52 1.Tsnnronvl.3-(2-isoDropv1phenvn-2-thioxo-iinidazolidin-4-one

The title compound was prepared by the procedure described in Example 45 using 10.0 g of 2-isopropylphenyl-isothiocyanate, 11.9 g of N-isopropyl glycine, 12.0 g of triethyl amine, and 200 mL of chloroform. Crystallization from ethanol afforded die tide compound (6.8 g) as a light pink solid, m.p. 112-1 14° C. Anal. Calcd. for.

Cl5 H20 N2 O S: C, 65.18; H, 7.29; N, 10.13. Found: C, 65.51; H, 7.25; N, 10.32.

Mass spectrum (EI, M.⁺) m/z 276.

EXAMPLE 53 1-Benzvl-3-U-hutvlphenvli-2-thioxo-imidazolidin-4-one

A mixture of N-benzyl glycine (8.7 g), 4-n-butylphenyl-isothiocyanate (8.55 g), trieuiyl amine (5.5 g) and chloroform (150 mL) was heated at reflux for 5 hours. The solvent was evaporated. The residue was dissolved in ediyl acetate (300 mL) and water (2x200 mL). The organic phase was dried over anhydrous magnesium sulfate and evaporated to dryness. Crystallization from etiiyl acetate afforded die tide compound (11.4 g) as an off-white solid, m.p. 149-151° C. Anal. Calcd. for. C20 H22 N2 O S: C, 70.97; H, 6.55; N, 8.28. Found: C, 70.81; H, 6.76; N, 8.32. Mass spectrum (EI, M.⁺) m/z 338. EXAMPLE 54 1 -BιιtvI-3-(5-chloro-2-methvlphenvn-2-thioxo-imidazolidin-4-one

2-Chloro acetic acid (47.3 g) was added portionwise while stirring to a n-butyl amine (500.0 g). The addition was carried over a period of 30 minutes. The mixture was stirred at ambient temperature for 18 hours. The excess n-butyl amine was evaporated leaving a viscous clear oil (120.0 g) which soUdified upon standing. The crude product consisted of a 1:1 mixture of N-butyl glycine and butyl amine hydrochloride. This product mixture was used without further purification for d e preparation of the tide compound, in the next paragraph, and for preparation of the tide compounds described in Example 55 and Example 56.

A mixture of N-butyl glycine (12.0 g), 5-chloro-2-methylphenyl-isothiocyanate (9.15 g), triethyl amine (12.0 g) and chloroform (200 mL) was heated at reflux for 5 hours. The solvent was evaporated. The residue was treated with dieuiyl ether (400 mL). The mixture was filtered. The solid was washed with diethyl ether tiien discarded. The filtrate was evaporated to dryness. Crystallization from ethanol afforded die tide compound (6.0 g) as a tan solid, m.p. 102-103° C. Anal. Calcd. for. Ci4 Hπ Cl N2

O S: C, 56.65; H, 5.77; N, 9.44. Found: C, 56.41; H, 5.97; N, 9.36. Mass spectrum (EI, M.+) m/z 296/298.

EXAMPLE 55 1 -Butvl.3-(4-nuoroohenvn-2-thioxo-imidazolidin.4-one

The title compound was prepared by the procedure described in Example 54 using 7.7 g of 4-fluorophenyl-isothiocyanate, 12.0 g of N-butyl glycine, 15.0 g of triethyl amine, and 250 mL of chloroform. CrystaUization from ethanol afforded die tide compound (5.9 g) as an off-white solid, m.p. 92-93° C. Anal. Calcd. for. C13 H15 F N2 O S: C, 58.62; H, 5.68; N, 10.52. Found: C, 58.23; H, 5.65; N, 10.56. Mass spectrum (EI, M.⁺) m/z 266. EXAMPLE 56 1.Bιιtvl-3-r2.chloro-6-methvlDhenvn-2-thioxo-imidazolidin.4-nn.>

The tide compound was prepared by d e procedure described in Example 54 using 6.5 g of 2-chloro-6-methylphenyl-isothiocyanate, 8.5 g of N-butyl glycine, 10.0 g of tried yl amine, and 150 mL of metiiylene chloride. Purification was achieved by flash chromatography on silica gel (methylene chloride). CrystaUization from ethanol afforded die tide compound (3.85 g) as a Ught pink solid, m.p. 97-100° C. Anal. Calcd. for. C14 Hπ Cl N2 O S : C, 56.65; H, 5.77; N, 9.44. Found: C, 56.45; H , 5.67; N, 9.33. Mass spectrum (+FAB, [M+H]+) m/z 297.

EXAMPLE 57

3.M-t-Butvlnhenvn-1 -methvl-2-thioxo-imidazolidin-4.onp

A mixture of sarcosine etiiyl ester hydrochloride (7.68 g), 4-t-butylphenyl- isod iocyanate (9.6 g), triethyl amine (10.1 g) and chloroform (250 mL) was heated at reflux for 3 hours. The mixture was cooled to ambient temperature, washed with 2N HCl (2x200 mL), tiien with water (200 mL). The organic phase was dried over anhydrous magnesium sulfate and evaporated to dryness. The residue was crystallized from ethanol to give the title compound (9.9 g), m.p. 156-158° C. Anal. Calcd. for Cl4 Hi8 N2 O S: C, 64.09; H, 6.91; N,10.68. Found: C, 63.83; H, 7.15; N, 10.53.

Mass spectrum (EI, M.⁺) m/z 262.

EXAMPLE 5ft 1.Ethvl-3-f2-methvlsulfanvlDhenvh-2-thioxo-imidazolidin-4.one

A mixture of N-ethyl glycine (9.23 g), 2-(methyldιio)-phenyl-isothiocyanate

(9.1 g), triethylamine (10.1 g) and metiiylene chloride (150 mL) was heated at reflux for 3 hours. The mixture was evaporated to dryness. The residue was recrystallized from etiianol to give the tide compound (6.5 g) as a creamy solid, m.p. 128-131° C.

Anal. Calcd. for. C12H14N2S2O: C, 52.1 1; H, 5.30; N, 10.52. Found: C, 52.28; H ,

5.26; N, 10.54. Mass spectrum (EI, M.+) m/z 266. EXAMPLE 59 1.Allvl-3-f2.6-dimethvlphenvn-2-thioxo-imida7olidin-4-one

Chloroacetic acid (27.5 g) was added portionwise over 5 minutes to a cooled solution of allylamine (114 g) in water (100 mL). The reaction mixture was stirred at ambient temperature for 48 hours. The mixture was tiien evaporated to a viscous oily residue (35 g). The crude product consisted of a 1 : 1 mixture of N-allyl glycine and allyl amine hydrochloride. This product mixture was used without further purification for the preparation of the title compound, in die next paragraph, and for preparation of d e titie compound described in Example 60.

A mixture of N-allyl glycine (17.4 g), 2,6-dimedιylphenyl-isothiocyanate (20 g), triethylamine (20.2 g), and methylene chloride (150 mL) was heated at reflux for 3 hours. The reaction mixture was evaporated to dryness. The residual gum was dissolved in dietiiyl ether, then treated widi etheral hydrogen chloride. A white soUd formed. The solid was filtered and discarded. The filtrate was concentrated to a residue. The residure was chromatographed on silica gel (CH2CI2) to give tide compound (5.2 g) as an orange solid, m.p. 43-46° C. Anal. Calcd. for. C14 Hi6 N2 OS: C, 64.59; H, 6.19; N, 10.76. Found: C, 64.52; H, 6.08; N, 10.66. Mass spectrum (EI, M.⁺) m/z 260.

EXAMPLE 60 l-Allvl-3-(5-chloro-2-methvlphenvh-2-thioxo-imidazolidin-4-nne

A mixture of N-allyl glycine (17.4 g), 5-chloro-2-methylphenyl-isothiocyanate (20.1 g), triethylamine (20.2 g), and metiiylene chloride (150 mL) was heated at reflux for 2 hours. The reaction mixture was evaporated to dryness. Purification was achieved by flash chromatography on silica gel (methylene chloride). Recrystallization from Hexane-EtOAc afford the title compound (4.8 g) as yellow solid, m.p. 106-109° C. Anal. Calcd. for. C13 H13 N2 O Cl S: C, 55.61; H, 4.67; N, 9.98. Found: C, 55.45; H, 4.56; N, 9.72. Mass spectrum (EI, M.+) m/z 280. EXAMPLE 01

3-r2.6.dimethvlDhenvn.l-(prop.2-vnvl ,.2-thioxn.imida7.nlidin.4-one

To a cooled solution of etiiyl bromoacetate (37.6 g) in diethyl ed er (75 mL), was added propargylamine (25 g). The mixture was stirred for 3 hour at 0-5° C. The reaction temperature was raised to ambient temperature, and the stirring continued for 18 hours. A solid formed. The solid was filtered and discarded. The filtrate was evaporated to dryness to give crude tide compound (30.1 g). The crude product was used widiout further purification for the preparation of die tide compound, in die next paragraph, and for preparation of the tide compounds described in Example 62 and Example 63.

A mixture of ethyl N-propargylaminoacetate (14.1 g), 2,6-dimethylphenyl- isothiocyanate (16.3 g), methylamine (10.1 g), and metiiylene chloride (150 mL) was heated at reflux for 3 hours. The reaction mixture was cooled to ambient temperature, washed widi IN HCl (100 mL), then with water. The organic layer was separated, dried over anhydrous magnesium sulfate, then evaporated to dryness. The residual oil was triturated with hexane. The solid was collected by filtration. RecrystalUzation from hexane-EtOAc afforded the title compound (12.5 g) as yellow solid, m.p. 117-121° C. Anal. Calcd. for. Cl4 H14N2S2 O: C, 65.09; H, 5.46; N, 10.84. Found: C, 65.23;

H, 5.43; N, 10.88. Mass spectrum (EI, M.+) m/z 258.

EXAMPLE 02 3-(5-chloro-2-methylDhenvn-l -(proD-2-vnvn-2-thioxo-imidazolidin-

4-one

A mixture of ethyl N-propargylaminoacetate (7.0 g), 5-chloro-2- methylphenylisothiocyanate (9.2 g), triethylamine (5.0 g), and methylene chloride (100 mL) was heated at reflux for 3 hours. The reaction mixture was cooled to ambient temperature, washed witii 1 N HCl (50 mL), then with water. The organic layer was dried over anhydrous magnesium sulfate, tiien evaporated to dryness. The residual oil was triturated with hexane. The solid was collected by filtration. Recrystallization from EtOAc afford the tide compound (5.1 g) as yellow solid, m.p. 131-134° C. Anal. Calcd. for. C13 Hn N₂ O Cl S: C, 56.01; H, 3.98; N, 10.05. Found: C, 55.90; H, 3.77; N, 9.92. Mass spectrum OΞI, M.+) m/z 278.

EXAMPLE 63

3-r4-chloro-2-methvlDhenvn-1 - Dron-2-vnvl)-2-thioxo-imida7olidin-

4-one

A mixture of ethyl N-propargylaminoacetate (10.0 g), 4-chloro-2- methylphenylisotiiiocyanate (12.9 g), triethylamine (7.1 g), and metiiylene chloride (150 mL) was heated at reflux for 3 hours. The reaction mixture was cooled to ambient temperature, washed with 1 N HCl (100 mL), then witii water. The organic layer was dried over anhydrous magnesium sulfate, tiien evaporated to dryness. The residual oil was triturated with hexane. The soUd was collected by filtration. RecrystalUzation from Hexane-EtOAc afford d e title compound (5.2 g) as yellow solid, m.p. 99-102° C. Anal. Calcd. for. C13 Hπ N O Cl S: C, 56.01; H, 3.98; N, 10.05. Found: C, 55.61; H, 3.83; N, 10.0. Mass spectrum (EI, M.+) m/z 278.

Claims

( 1 ) A compound of formula I :

wherein

R is alkyl of 1 to 6 carbon atoms; a substituted or unsubstituted aromatic N, O or S heterocycle having 4 to 6 carbon and one hetero ring members; substituted or unsubstituted aryl of 6 to 10 carbon atoms, arylalkyi of 7 to 12 carbon atoms, benzhydryl or indanyl, in which die substituents are one to three members independendy selected from die group consisting of alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkylthio of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, halo, perfluoroalkyl of 1 to 6 carbon atoms, perfluoroalkoxy of 1 to 6 carbon atoms or hydroxy; and

Rl is aryl of 6 to 10 carbon atoms, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms or substituted aryl of 6 to 10 carbon atoms where die substituents are one to three members independendy selected from d e group consisting of alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon ations, alkylthio of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon atoms, halo, perfluoroalkyl of 1 to 6 carbon atoms, perfluoroalkoxy of 1 to 6 carbon atoms or hydroxy, for use in the treatment of mammals.

(2) A compound according to claim 1 wherein the treatment is for increasing die HDL cholesterol concentration in the blood of a mammal in need of increased HDL cholesterol blood concentration.

(3) A compound of Claim 1 or 2 in which said compound is of formula I in which R is substituted phenyl where the substituents are two members of the group consisting of alkyl of 1 to 6 carbon atoms,perfluoroalkoxy of 1 to 6 carbon atoms, halo, or ortho substituted trimethylene or tetrametiiylene and R is alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms or alkynyl of 2 to 6 carbon atoms.

(4) A compound of Claim 1 or 2 in which said compound is of formula I in which R is substituted phenyl where d e substituents are a halo and an alkyl group of 1 to 3 carbon atoms or orti o substituted trimethylene and R is alkyl of 1 to 3 carbon atoms, alkenyl of 2 to 4 carbon atoms or alkynyl of 2 to 4 carbon atoms.

(5) A compound of Claim 1 or 2 in which said compound is of formula I in which R is substituted phenyl where die substituents are chloro or fluoro in d e 4- or 5- position and an alkyl group of 1 to 3 carbon atoms and R is alkyl of 1 to 3 carbon atoms, alkenyl of 2 to 4 carbon atoms or alkynyl of 2 to 4 carbon atoms.

(6) A compound of Claim 1 or 2 in which said compound is selected from the group consisting of:

3-(5-Chloro-2-methylphenyl)-l-methyl-2-thioxo-imidazoUdin-4-one; 3-(3-Chloro-2-metiιylphenyl)-l-med yl-2-thioxo-imidazoUdin-4-one; 3-(4-Chloro-2-methylphenyl)-l-methyl-2-thioxo-imidazoUdin-4-one; 3-(Indan-5-yl)- 1 -methyl-2-thioxo-imidazolidin-4-one; 3-(2,6-Diisopropylphenyl)- 1 -medιyl-2-thioxo-imidazoUdin-4-one; 3-(2-Etiιyl-6-isopropylphenyl)-l-methyl-2-thioxo-imidazolidin-4-one; 3-(2-Ethyl-6-medιylphenyl)- 1 -methyl- 2-thioxo-imidazoUdin-4-one; 3-(5-Chloro-2-med ylphenyl)- 1 -ethyl-2-thioxo-imidazolidin-4-one; 3-(2,6-Dichlorophenyl)- 1 -ethyl-2-dιioxo-imidazolidin-4-one; l-Ethyl-3-(4-fluorophenyl)-2-thioxo-imidazolidin-4-one; l-Ethyl-2-thioxo-3-(4-trifluoromethoxyphenyl)-imidazolidin-4-one; 3-(2,6-Dimethylphenyl)- 1 -etiiyl-2-thioxo-imidazolidin-4-one; l-Edιyl-3-isobutyl-2-thioxo-imidazolidin-4-one; 3-(2-Chlorophenyl)-l-ethyl-2-thioxo-imidazolidin-4-one; l-Edιyl-3-(2-tolyl)-2-thioxo-imidazoUdin-4-one; 3-(2-Chloro-6-methylphenyl)- 1 -ethyl-2-thioxo-imidazolidin-4-one; l-Edιyl-3-(5-fluoro-2-med ylphenyl)-2-d ioxo-imidazolidin-4-one; 3-(2,6-Diisopropylphenyl)- 1 -ethyl-2-thioxo-imidazolidin-4-one; l-Emyl-2-thioxo-3-(2-trifluoromethylphenyl)-imidazoUdin-4-one; l-Ethyl-3-(2-chlc«>-6-methylphenyl)-2-tiιioxo-imidazolidin-4-one; 3-(2-Ethyl-4-metiiylphenyl)-l-ethyl-2-thioxo-imidazolidin-4-one; 3-(2,4-Dichlorophenyl)- 1 -ed yl-2-dιioxo-imidazolidin-4-one; 3-(2,4-Dimetirylphenyl)- 1 -edιyl-2-thioxo-imidazoUdin-4-one; 3-(2,5-Dimethylphenyl)- 1 -ethyl-2-thioxo-imidazoUdin-4-one; l-Ethyl-2-dιioxo-3-(2,4,5-trimethylphenyl)-imidazoUdin-4-one; l-Ed yl-3-(2-isopropylphenyl)-2-thioxo-imidazolidin-4-one; l-Ethyl-3-(2-ethylphenyl)-2-dιioxo-imidazoUdin-4-one; 3-(5-Chloro-2-methylphenyl)-l-phenyl-2-thioxo-imidazolidin-4-one; 3-(5-Chloro-2-methylphenyl)- 1 -isopropyl-2-thioxo-imidazolidin-4-one; 3-(2,6-Dimethylphenyl)- 1 -isopropyl-2-thioxo-imidazoUdin-4-one; 3-(2-Edιyl-6-methylphenyl)-l-isopropyl-2-thioxo-imidazolidin-4-one; l-Butyl-3-(4-fluorophenyl)-2-thioxo-imidazolidin-4-one; l-AUyl-3-(2,6-dimethylphenyl)-2-tiiioxo-imidazoUdin-4-one; 3-(2,6-Dimethylphenyl)-l-(prop-2-ynyl)-2-dιioxo-imidazolidin-4-one; 3-(3-Qιloro-4-metiιylphenyl)- 1 -medιyl-2-uiioxo-imidazolidin-4-one 3-(2-Ethylphenyl)- 1 -methyl-2-thioxo-imidazoUdin-4-one l-Methyl-3-(2-isopropylphenyl)-2-thioxo-imidazolidin-4-one 3-(4-t-Butylphenyl)- 1 -methyl-2- thioxo- imidazolidin-4-one l-Allyl-3-(5-chlOTO-2-methylphenyl)-2-thioxo-imidazolidin-4-one 3-(5-Chloro-2-methylphenyl)- 1 -(prop-2-ynyl)-2-dιioxo-imidazolidin-4-one; or l-Ethyl-3-(2-ethyl-6^isopropylphenyl)-2-thioxo-imidazolidin-4-one. 3-(2-chloro-6-methylphenyl)- 1 -methyl-2-thioxo-imidazolidin-4-one. 3-(2,6-dimethylphenyl)- 1 -methyl-2-thioxo-imidazolidin-4-one.

(7) Use of a compound of formula I as defined in any of claims 1 to 6 for the manufacture of a medicament for increasing die HDL cholesterol concentration in the blood of a mammal in need of increased HDL cholesterol blood concentration.

(8) A pharmaceutical composition comprising a compound of die formula I as defined in any of claims 1 to 6 and a pharmaceutically acceptable carrier.

(9) A method for increasing the HDL cholesterol concentration in the blood of a mammal in need of increased HDL cholesterol blood concentration, which comprises administering to said mammal, orally or parenterally, a compound of formula I as defined in any of claims 1 to 6.

(10) A compound of formula I:

wherein

Rl is alkyl of 1 to 6 carbon atoms and R is alkyl of 1 to 6 carbon atoms, naphthyl, benzhydryl, fluorophenylmethyl, phenethyl, l-(fluorophenyl)ethyl, 5-chloro-2- medioxyphenyl, trifluoromethoxyphenyl, trifluoromethylphenyl, metiiylsulfanylphenyl, pyridyl or the group of formula II

where R², R^ and R⁴ togetiier are 2-chloro, 4-fluoro, 2,4-chloro or 2,6- chloro, or

R² is hydrogen, R^ is a halogen in 3-position and R⁴ is alkyl of 1 to 6 carbon atoms in

4-position, or R² is alkyl of 1 to 6 carbon atoms and R^ and R⁴ are, independendy, hydrogen or alkyl of 1 to 6 carbon atoms or R^ is a halogen and R⁴ is hydrogen; or

Rl is alkenyl of 2 to 6 carbon atoms, R is is the group of formula II where R² is alkyl of 1 to 6 carbon atoms and R^ and R⁴ are, independendy, hydrogen or alkyl of 1 to 6 carbon atoms, or R² is hydrogen and R3 and R⁴ taken together are ortho substituted trimethylene or tetramethylene, or R² is alkyl of 1 to 6 carbon atoms, R^ is halogen and R⁴ is hydrogen, or R² is hydrogen, R3 is halogen in 3-position and

R⁴ is alkyl of 1 to 6 carbon atoms in 4-position; or when Rl is alkynyl of 2 to 6 carbon atoms, R is a group of formula II where any two of R², R^ and R⁴ are, independendy, alkyl of 1 to 6 carbon atoms, halo, perfluoralkyl of 1 to 6 carbon atoms, perfluoralkoxy of 1 to 6 carbon atoms, or, taken together, are ortho substituted trimethylene or tetramethylene; or when Rl is aryl of 6 to 10 carbon atoms or arylalkyi of 7 to 12 carbon atoms, R is die group of formula II where R² is alkyl of 1 to 6 carbon atoms, R^ is a halogen and R⁴ is hydrogen, or R² is hydrogen, R^ is a halogen in 3-position and R⁴ is alkyl of 1 to 6 carbon atoms in 4- position.

(11) A compound according to Claim 10 of formula:

in which

Rl is alkyl of 1 to 6 carbon atoms or alkenyl of 2 to 6 carbon atoms;

R² is alkyl of 1 to 6 carbon atoms and R^ and R⁴ are, independendy, hydrogen or alkyl of 1 to 6 carbon atoms; or R² is hydrogen and R^ and R⁴ taken together are ortho substituted trimethylene or tetramethylene.

(12) A compound according to Claim 11 in which R^ and R⁴ are hydrogen, R^ is methyl or ethyl and R² is alkyl of 1 to 3 carbon atoms.

(13) The compound according to Claim 11 or 12 which is 3-(2-ethylphenyl)- 1 -metiιyl-2-tiιioxo-imidazolidin-4-one. l-meuiyl-3-(2-isopropylphenyl)-2-ώioxo-imidazolidin-4-one. l-ethyl-3-(2-tolyl)-2-thioxo-imidazoUdin-4-one. l-ethyl-3-(2-isopropylphenyl)-2-ti ioxcHjiτύdazolidin-4-one. l-ed yl-3-(2-ethylphenyl)-2-d ioxo-imidazoUdin-4-one.

(14) A compound according to Qaim 11 in which R⁴ is hydrogen , Rl is metiiyl, ethyl or allyl, R² is alkyl of 1 to 3 carbon atoms and R^ is alkyl of 1 to 3 carbon atoms or R² is hydrogen and R3 and R⁴ are ortho substituted trimethylene or tetramethylene.

(15) The compound according to Claim 14 which is 3-(2-ethyl-6-methylphenyl)- 1 -methyl-2-thioxo-imidazolidin-4-one. 3-(2,6-dimethylphenyl)-l-ethyl-2-thioxo-imidazoUdin-4-one. 3-(2,6-dimethylphenyl)- 1 -isopropy l-2-thioxo-imidazolidin-4-one . l-allyl-3-(2,6-dimedιylphenyl)-2-thioxo-imidazolidin-4-one. 3-(2-ethyl-6-isopropylphenyl)- 1 -methyl-2-thioxo-imidazolidin-4-one. l-edιyl-3-(2-ethyl-6-isopropylphenyl)-2-thioxo-imidazolidin-4-one.

(16) A compound according to Claim 11 in which Rl is methyl, ediyl or allyl and R², R3 and R⁴ are , independently, alkyl of 1 to 3 carbon atoms.

(17) A compound according to Claim 16 which is l-ethyl-2-thioxo-3-(2,4,5- trimethylphenyl)-imidazolidin-4-one.

(18) A compound according to Qaim 10 of formula :

in which

R^Ϊ is alkyl of 1 to 6 carbon atoms; R² and R^ represent 2,4-dichloro or 2,6-dichloro; or R² is 2-chloro or 4-fluoro and R^ is hydrogen.

(19) The compound according to Claim 18 which is 3-(2,6-dichlorophenyl)- 1 -ed yl-2-dιioxo-imidazoIidin-4-one; l-edιyl-3-(4-fluσrophenyl)-2-uiioxo-irnidazoUdin-4-one; 3-(2-chlorophenyl)- 1 -ethyl-2-thioxo-imidazoUdin-4-one; 3-(2,4-dichlorophenyl)- 1 -ethyl-2-thioxo-imidazolidin-4-one; 3-(4-fluorophenyl)- 1 -isopropyl-2-thioxo-imidazolidin-4-one; l-butyl-3-(4-fluorophenyl)-2-dιioxo-imidazoUdin-4-one.

(20) A compound according to Claim 10 of formula:

in which

Rl is alkynyl of 2 to 6 carbon atoms; and

R² and R^ are, independendy, alkyl of 1 to 6 carbon atoms, halo, perfluoralkyl of 1 to 6 carbon atoms, perfluoralkoxy of 1 to 6 carbon atoms, or, taken together, R² and R^ are ordio substituted trimethylene or tetramethylene.

(21) A compound of according to Claim 20 in which R^ is ethynyl, propargyl or butynyl.

(22) The compound according to Claim 20 or 21 which is 3-(2,6-dimed ylphenyl)-l-(prop-2-ynyl)-2-thioxo-imidazolidin-4-one; 3-(5-chloro-2-methylphenyl)-l-(prop-2-ynyl)-2-thioxo-imidazolidin-4-one; 3-(4-chloro-2-methylphenyl)-l-(prop-2-ynyl)-2-thioxo-imidazolidin-4-one;

(23) A compound according to Claim 10 of formula:

in which

R¹ is alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms, aryl of 6 to

10 carbon atoms or arylalkyi of 7 to 12 carbon atoms;

R² is alkyl of 1 to 6 carbon atoms, R^ is a halogen and R⁴ is hydrogen; or R² is hydrogen, R^ is a halogen in 3-position and R⁴ is alkyl of 1 to 6 carbon atoms in 4-position.

(24) A compound according to Claim 23 in which R is alkyl of 1 to 3 carbon atoms, allyl or phenyl, R² is alkyl of 1 to 3 carbon atoms, R^ is chloro or fluoro and R⁴ is hydrogen.

(25) The compound according to Claim 23 or 24 which is 3-(5-chloro-2-methylphenyl)- 1 -methyl-2-thioxo-imidazolidin-4-one. 3-(3-chloro-2-methylphenyl)-l-methyl-2-thioxo-imidazolidin-4-one. 3-(4-chloro-2-methylphenyl)-l-methyl-2-dιioxo-imidazolidin-4-one. 3-(5-chloro-2-methylphenyl)-l-ethyl-2-thioxo-imidazolidin-4-one. 3-(2-chloro-6-methylphenyl)-l-ethyl-2-thioxo-imidazolidin-4-one. l-ethyl-3-(5-fluoro-2-methylphenyl)-2-d ioxo-imidazolidin-4-one. 3-(5-chloro-2-methylphenyl)- 1 -phenyl-2-thioxo-imidazoUdin-4-one. 3-(5-chloro-2-methylphenyl)-l-isopropyl-2-thioxo-imidazolidin-4-one. l-Allyl-3-(5-chloro-2-methylphenyl)-2-thioxo-imidazolidin-4-one

(26) A compound according to Claim 10 of formula I in which Rl is alkyl of 1 to 6 carbon atoms; and R is alkyl of 1 to 6 carbon atoms, naphthyl, benzhydryl, fluorophenylmethyl, phenethyl, l-(fluorophenyl)ethyl, 5-chloro-2-methoxyphenyl, trifluoromethoxyphenyl, trifluoromethylphenyl, methylsulfanylphenyl or pyridyl.

(27) A compound according to Claim 26 in which Rl is alkyl of 1 to 6 carbon atoms; and R is alkyl of 1 to 6 carbon atoms, 2-naphthyl, benzhydryl, 4-fluorophenylmethyl, phenethyl, l-(4-fluorophenyl)ethyl, 5-chloro-2-methoxyphenyl, 4-trifluoro- methoxyphenyl, 2-trifluoromethylphenyl, 2-methylsulfanylphenyl or 3-pyridyl.

(28) The compound according to Qaim 26 or 27 which is 3-benzhydryl- 1 -medιyl-2-thioxo-imidazolidin-4-one; l-methyl-3-(pyridin-3-yl)-2-thioxo-imidazolidin-4-one; 3-(5-chloro-2-methoxyphenyl)- 1 -methyl-2-dιioxo-imidazolidin-4-one; 3-(5-chloro-2-medιoxyphenyl)- 1 -ethyl-2-thioxo-imidazolidin-4-one; l-ethyl-2-dιioxo-3-(4-trifluoromethoxyphenyl)-imidazolidin-4-one; l-ethyl-3-(4-fluorobenzyl)-2-thioxo-imidazolidin-4-one; l-ethyl-3-isobutyl-2-thioxo-imidazoIidin-4-one; l-ethyl-3-(naphthalen-2-yl)-2-thioxo-imidazoUdin-4-one; l-ethyl-2-thioxo-3-(2-trifluoromethylphenyl)-imidazolidin-4-one;

1 -ethyl-3-[ 1 -(4-fluorophenyl)-ethyl]-2-thioxo-imidazolidin-4-one; l-ethyl-3-phenethyl-2-thioxo-imidazolidin-4-one; l-edιyl-3-(2-methylsulfanylphenyl)-2-thioxo-imidazolidin-4-one.

(29) Process for die preparation of a compound as defined in any of claims 1 to 28 comprising reacting the corresponding compound of formula A

CO₂R²

> ' X

(A)

in which R² is as defined in any of claims 1 to 28 and X is halogen, with R1-NH2 in which Rl is as defined in any of claims 1 to 28, to give a compound of formula 2(a)

(2a)

in which R and R² are as previously defined herein and reacting the compound of formula 2(a) with R-NCS in the presence of a base to provide either the compound of formula (3 a)

(3a)

or of formula (4)

N N_v

(4) \

R^/ Υ ^V R' S

and thereafter cyclising the compound of formula (3a) to the compound of formula (4) by refluxing in the presence of a base.